Ignite Creation Date:
2024-05-06 @ 3:20 AM
Last Modification Date:
2024-10-26 @ 11:32 AM
Study NCT ID:
NCT02264002
Status:
COMPLETED
Last Update Posted:
2014-10-15
First Post:
2014-10-13
Brief Title:
Pharmacodynamic Effects Safety and Tolerability of Cilobradine Compared to Metoprolol Succinate and Placebo in Healthy Volunteers
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
Pharmacodynamic Effects Safety and Tolerability of 025 mg 05 mg 1 mg and 2 mg Cilobradine Compared to 190 mg Metoprolol Succinate and Placebo Administered po Once Daily Over 14 Days to Healthy Volunteers in a Randomised Placebo-controlled Partly Double Blind Study With a 4 mg14 mg and 10 mg20 mg Cilobradine Single Dose Versus Placebo Substudy Double Blind Three-fold Cross-over
Status:
COMPLETED
Status Verified Date:
2014-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Pharmacodynamic effects on heart rate HR at rest and during exercise and on flicker fusion frequency FFF FFF method evaluation
Safety tolerability and pharmacokinetics of cilobradine
Safety tolerability and pharmacokinetics of cilobradine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None